Sugi Predict

Sugi Predict / Compounds / SCHEMBL78221

SCHEMBL78221

SCHEMBL78221

O=C(O)c1cc(C(F)(F)F)ccc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MRGPRX4 Q96LA9 3/20 0.61
▸ ALDH1A1 P00352 4/20 0.58
▸ KDM4E B2RXH2 3/20 0.58
▸ HPGD P15428 3/20 0.58
▸ HSD17B10 Q99714 2/20 0.58
▸ TP53 P04637 1/20 0.57
▸ JAK2 O60674 1/20 0.55
▸ JAK1 P23458 1/20 0.55
▸ TYK2 P29597 1/20 0.55
▸ SORT1 Q99523 1/20 0.52
▸ CES2 O00748 2/20 0.52
▸ USP2 O75604 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ NPC1 O15118 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ ANO1 Q5XXA6 1/20 0.48
▸ KCNMA1 Q12791 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18861026 0.98 MRGPRX4 (0.59) MRGPRX4ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL10658142 0.86 JAK2 (0.56) MRGPRX4ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL477732 0.85 JAK2 (0.55) MRGPRX4ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL1818435 0.85 KDM4E (0.62) MRGPRX4ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL30740081 0.83 JAK2 (0.57) MRGPRX4ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL6553697 0.83 KDM4E (0.61) MRGPRX4ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL1199588 0.83 JAK2 (0.57) MRGPRX4ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL8617573 0.83 KDM4E (0.61) MRGPRX4ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL30094862 0.83 JAK2 (0.54) MRGPRX4ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL629096 0.83 CASP1 (0.55) MRGPRX4ALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 — — EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 — — WO claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 — — CN claimed
CN-116396159-A Synthesis method of 2,2' -biphenyl dicarboxylic acid compound 湖南大学 2023-07-07 — — CN claimed
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 — — EP claimed
EP-3049386-B9 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-11-18 — — EP claimed
EP-3049386-B1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-07-22 — — EP claimed
EP-3551634-A1 SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2019-10-16 — — EP claimed
EP-3551633-A1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2019-10-16 — — EP claimed
CN-110088108-A SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-02 — — CN claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 — — WO claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 — — US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 — — US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 — — US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 — — US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 — — US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 — — US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 — — US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 — — US claimed
US-5897940-A Ink jet transparencies XEROX CORPORATION (US) 1999-04-27 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 MRGPRX4 544/4885ALDH1A1 1569/4885KDM4E 1814/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 MRGPRX4 3647/4885ALDH1A1 1723/4885KDM4E 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.